AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Tumor-Specific Vaccines Under Development.(Brief Article)
2001 JAN 24 - (NewsRx.com & NewsRx.net) -- BioPulse International, Inc., (BIOP), San Ysidro, California, announced the development of multiple Tumor-Specific Cancer Vaccines (TSV).
The vaccines are based on the company's dendritic cell cancer vaccine technology. These vaccines will potentially offer additional alternatives to cancer patients.
Cancer vaccines that have been under investigation by BioPulse previously used only patient-specific tumor antigens. This approach provides a customized and specific vaccine product for each patient. The new tumor-specific vaccines use a combination of tumor antigens designed to target a class of tumors. This strategy potentially allows for a single vaccine to be useful to a variety of patients that share a common tumor type.
"The significance of this development is that it offers the potential of an ...
- New company to develop, produce patient-specific cancer vaccines.
- Newspaper article from: Life Science Weekly December 7, 2004 700+ words
...produce and distribute customized cancer vaccines, including a melanoma vaccine, to...tumor cells that they represent. ODC cancer vaccines are produced by removing dendritic...for the production of personalized cancer vaccines and tested these novel therapies in...
- Baylor Health Care System Forms Biotech Company to Develop and Produce...
- Press release article from: PR Newswire November 1, 2004 700+ words
...produce and distribute customized cancer vaccines, including a melanoma vaccine, to...tumor cells that they represent. ODC cancer vaccines are produced by removing dendritic...for the production of personalized cancer vaccines and tested these novel therapies in...
- Biomira Initiates Exploratory Phase Ib Trial With Patient-Specific Cancer...
- Newspaper article from: Vaccine Weekly October 10, 2001 700+ words
...first step, carried out at NCI under the direction of Dr. Larry Kwak, the study showed that a highly purified patient-specific cancer antigen could be produced and formulated by a patented process into a liposomal formulation that also contains the potent...
- Biomira Initiates Exploratory Phase Ib Trial With Patient-Specific Cancer...
- Newspaper article from: Cancer Weekly October 9, 2001 700+ words
...first step, carried out at NCI under the direction of Dr. Larry Kwak, the study showed that a highly purified patient-specific cancer antigen could be produced and formulated by a patented process into a liposomal formulation that also contains the potent...
- Biomira Announces Initiation of Exploratory Phase Ib Trial with...
- Press release article from: PR Newswire September 10, 2001 700+ words
...first step, carried out at NCI under the direction of Dr. Larry Kwak, the study showed that a highly purified patient-specific cancer antigen could be produced and formulated by a patented process into a liposomal formulation that also contains the potent...
- BioPulse Announces Important Development of New Cancer Vaccines Clinical Trials...
- Press release article from: PR Newswire January 5, 2001 700+ words
...development of multiple Tumor-Specific Cancer Vaccines (TSV). The vaccines...tumor- and patient-specific cancer vaccines may be warranted." Several...trials of the tumor-specific cancer vaccines outside the United States...
- Cancer Vaccines.
- Magazine article from: Chemical Market Reporter Arnum, Patricia Van May 10, 1999 700+ words
...goal. However, tumor-specific cancer treatments have gained acceptance...melanoma is a primary focus in cancer vaccines. A broadly effective melanoma...Other key applications for cancer vaccines include breast, ovarian...significant position in cancer vaccines include ...
- Cancer Vaccines: A Shot in the Dark?
- Press release article from: M2 Presswire April 14, 2005 700+ words
...April 2005-DATAMONITOR: Cancer Vaccines: A Shot in the Dark...Consequently, three quarters of cancer vaccines currently in the development...formulation." Antigen-specific cancer vaccines dominate all phases of development...
